Aardvark Therapeutics’ (AARD) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $6.00 price target on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.80) EPS, Q1 2027 earnings at ($0.72) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.98) EPS.

A number of other research firms have also recently commented on AARD. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Morgan Stanley restated an “underweight” rating and set a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. Finally, B. Riley Financial decreased their price objective on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Aardvark Therapeutics presently has an average rating of “Hold” and an average price target of $16.30.

Aardvark Therapeutics Stock Up 6.6%

Shares of AARD opened at $6.48 on Monday. The company has a 50 day moving average of $4.82 and a two-hundred day moving average of $7.37. Aardvark Therapeutics has a twelve month low of $3.35 and a twelve month high of $17.94. The company has a market cap of $141.78 million, a price-to-earnings ratio of -2.02 and a beta of 3.93.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. On average, sell-side analysts expect that Aardvark Therapeutics will post -3.48 EPS for the current year.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in Aardvark Therapeutics during the first quarter valued at approximately $153,000. Geode Capital Management LLC boosted its position in Aardvark Therapeutics by 129.7% in the 2nd quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock worth $1,851,000 after purchasing an additional 77,327 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth approximately $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth approximately $42,000. Finally, Bank of America Corp DE grew its stake in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after purchasing an additional 3,369 shares during the period.

Aardvark Therapeutics News Summary

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and $6.00 price target on Aardvark Therapeutics, while issuing earnings estimates for 2026-2027. The firm also nudged its Q4 2026 EPS estimate higher, which may have helped sentiment around the stock. MarketBeat AARD report
• Neutral Sentiment: HC Wainwright’s forecasts still point to continuing losses over the next several quarters, with FY2026 EPS estimated at ($3.80) and FY2027 at ($1.98), underscoring that Aardvark remains a pre-profit biotech story. MarketBeat AARD report
• Negative Sentiment: Investor focus is still being weighed down by the FDA clinical hold on Aardvark’s lead Prader-Willi Syndrome candidate, a development that previously triggered a sharp selloff and continues to create uncertainty around the company’s pipeline. PR Newswire article

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.